Piper Sandler: Not declaring victory on Gilead's remdesivir yet, but this is another positive signal

Piper Sandler biotech analyst Tyler Van Buren discusses the implications of the reports of promising results in a study involving COVID-19 patients treated with Gilead's drug remdesivir.
Fri, Apr 17 20206:24 AM EDT